Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level

Haematologica

Volumn 89, Issue 7, 2004, Pages 880-881

  Santamaría, Amparo ^a,b   Martínez Rubio, Antonio ^a   Borrell, Montserrat ^a   Mateo, José ^a   Ortín, Rosa ^a   Fontcuberta, Jordi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Arterial; Coronary; TAFI; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CARBOXYPEPTIDASE U; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 3242780163     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Bouma BN, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procaroxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003;1:1566-74.
2. Mosnier LO, van der Borne PA, Meijers J, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80:829-35.
3. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe. Arterioscler Thromb Vasc Biol 2002;22:867-73.
4. Morange PE, Juhan-Vahue I, Scarabin PY, Alessi MC Luc G, Arveiler D, et al. Association between TAFI antigen and Ala I 47Thr polymorphism of the TAFI gene and the angina pectoris incidence. (The PRIME study). Thromb Haemost 2003;89:554-60.
5. Brouwers GJ, Leebeek FG, Tanck MW, Wouterjukema J, Kluft C, de Maat MM. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. The APRAIS study. Thromb Haemost 2003;90:92-100.